{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:34:51Z","timestamp":1791308091476,"version":"4.3.1"},"reference-count":43,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2004,9,22]],"date-time":"2004-09-22T00:00:00Z","timestamp":1095811200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> FEIBA<jats:sup>\u00ae<\/jats:sup>(factor eight inhibitor bypassing activity) has a history of more than 30\u2003years of successful use in controlling bleeding in haemophilic patients who have developed inhibitory antibodies against factor (F)VIII or FIX. Recently it was shown that FEIBA<jats:sup>\u00ae<\/jats:sup> contains the proenzymes of the prothrombin complex factors, prothrombin, FVII, FIX and FX, but only very small amounts of their activation products, with the exception of FVIIa, which is contained in FEIBA<jats:sup>\u00ae<\/jats:sup> in greater amounts. FEIBA<jats:sup>\u00ae<\/jats:sup> controls bleeding by induction and facilitation of thrombin generation, a process for which FV is crucial. A number of biochemical <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> studies have shown that FXa and prothrombin play a critical role in the activity of FEIBA<jats:sup>\u00ae<\/jats:sup>. Consequently, they are considered to be key components of this product. The prothrombinase complex has been found to be a major target site for FEIBA<jats:sup>\u00ae<\/jats:sup>. Apart from prothrombin and FXa, FEIBA<jats:sup>\u00ae<\/jats:sup> contains other proteins of the prothrombin complex, which could also facilitate haemostasis in haemophilia patients with inhibitors.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2004.00934.x","type":"journal-article","created":{"date-parts":[[2004,9,22]],"date-time":"2004-09-22T15:37:30Z","timestamp":1095867450000},"page":"3-9","source":"Crossref","is-referenced-by-count":154,"title":["FEIBA<sup>\u00ae<\/sup>: mode of action"],"prefix":"10.1111","volume":"10","author":[{"given":"P. L.","family":"Turecek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"V\u00e1radi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. P.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,9,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1001\/jama.1969.03160100038010","article-title":"Prothrombin concentrates in treatment of Christmas disease and allied disorders","volume":"208","author":"Breen FA","year":"1969","journal-title":"JAMA"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.137.9.1211"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.236.18.2061"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197407252910402"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197411142912014"},{"key":"e_1_2_6_7_2","unstructured":"FeketeLF HolstSL PeetoomF De VeberLI.\u2018Auto\u2019 factor IX concentrate: a new therapeutic approach to treatment of hemophilia A patients with inhibitors. International Congress of Hematology Sao Paulo 1972; 295 [Abstract]."},{"key":"e_1_2_6_8_2","unstructured":"ElsingerF.Shortening of clotting times of hemophilia A plasma with inhibitors induced by activated factor IX concentrates (Fraction FEIBA). ICTH Task Force MeetingClinical Use of FIX Concentrates Paris July 20 1975 [Oral presentation]."},{"key":"e_1_2_6_9_2","unstructured":"ElsingerF.Zum Wirkungsmechanismus von Fraktion FEIBA. In:LandbeckG MarxR. 6th Symposium on Haemophilia Hamburg 1975 Immuno GmbH Heidelberg 1976; 91\u20134."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(82)90240-7"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00532.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(84)90047-1"},{"key":"e_1_2_6_13_2","first-page":"829","article-title":"Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma","volume":"96","author":"Muntean W.","year":"1984","journal-title":"Wien Klin Wochenschr"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood.V59.2.401.401","article-title":"The coagulant\u2010active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits","volume":"59","author":"Giles AR","year":"1982","journal-title":"Blood"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1055\/s-0037-1615363","article-title":"Measurement of active coagulation factors in Autoplex\u2010T with colorimetric active site\u2010specific assay technology","volume":"80","author":"Lundblad RL","year":"1998","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_16_2","first-page":"589","article-title":"Activated prothrombin complex preparations for the treatment of anticoagulant hemophilia. Preparation \u2013 method of operation \u2013 supply possibility","volume":"117","author":"Wilms K","year":"1990","journal-title":"Folia Haematol Int Mag Klin Morph Blutforsch"},{"key":"e_1_2_6_17_2","first-page":"581","article-title":"Contribution to the mechanism of the \u2018factor VIII bypassing activity\u2019 (FEIBA) reaction","volume":"117","author":"Sander W","year":"1990","journal-title":"Folia Haematol Int Mag Klin Morph Blutforsch"},{"key":"e_1_2_6_18_2","first-page":"297","volume-title":"Advances in Experimental Medicine and Biology \u2013 Inhibitors to Coagulation Factors.","author":"Turecek PL","year":"1995"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1642666"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00450.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000071637"},{"key":"e_1_2_6_22_2","first-page":"279","article-title":"The prothrombin 20210A allele influences clinical manifestations of hemophilia A in patients with intron 22 inversion and without inhibitors","volume":"87","author":"Tizzano EF","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.4.1183.bloodjournal8841183"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-0037-1619560","article-title":"Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations?","volume":"23","author":"Nowak\u2010Gottl U","year":"2003","journal-title":"Hamostaseologie"},{"key":"e_1_2_6_25_2","unstructured":"TurecekPL V\u00e1radiK SchwarzHP.Prothrombin\u2010factor Xa complex \u2013 the active principle behind APCCs. A review and summary of current data.J Thromb Thrombolysis2004; in press."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1981.tb29750.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(88)90567-3"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000056722"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613347"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656010"},{"key":"e_1_2_6_31_2","first-page":"1038","article-title":"Recombinant human FVIIa dose dependently shortens the bleeding time in a rabbit model of antibody induced hemophilia A","volume":"328","author":"Kristensen AT","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00298.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200210000-00012"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.10.3698.bloodjournal88103698"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.45.26883"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00254.x"},{"issue":"1","key":"e_1_2_6_37_2","first-page":"526a","article-title":"Persistent survival of platelet factor Va activity in plasma","volume":"88","author":"Liu L","year":"1996","journal-title":"Blood"},{"issue":"1","key":"e_1_2_6_38_2","first-page":"520a","article-title":"Prothrombin mediates the binding of factor XI to human platelets and its activation by thrombin","volume":"88","author":"Baglia FA","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi972113"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(80)90151-6"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi000245o"},{"key":"e_1_2_6_42_2","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood.V73.7.1888.1888","article-title":"Activation of human factor VII by factors IXa and Xa on human bladder carcinoma cells","volume":"73","author":"Wildgoose P","year":"1989","journal-title":"Blood"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0925-4439(92)90019-J"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615947"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2004.00934.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2004.00934.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T12:22:47Z","timestamp":1695730967000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2004.00934.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":43,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1111\/j.1365-2516.2004.00934.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2004.00934.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}